toxic epidermal necrolysis

Pharmigene said last week that 50 hospitals in Taiwan will now administer its test for HLA-B*1502, which is a marker for increased risk of adverse events in Asian populations treated with the anti-seizure drug carbamazepine.

The Mayo Clinic will develop tests to detect for the presence of alleles that increase the risk for developing the potentially deadly skin disease if certain drugs are taken.

The data, analyzed from biological samples donated by GlaxoSmithKline, is available on SAEC's website for free, and the group plans to publish the associations later this year. However, an SAEC official said "it would be preliminary to develop a meaningful diagnostic chip off this data."

US News & World Report writes that genetic testing of lung tumors can help identify treatments for patients.

A team of researchers plans to sample Loch Ness for environmental DNA, according to Newsweek.

The New York Times writes about the appearance of mosaicism in healthy people.

In PNAS this week: insecticide resistance patterns Anopheles gambiae mosquito, transcriptome patterns in Pseudomonas aeruginosa during infection, and more.